Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 651-657

  Richards, Jon M ^a   Gale, Danielle ^a   Mehta, Nilesh ^a   Lestingi, Timothy ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DEPIGMENTATION; DRUG EFFECT; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033044110     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.651     Document Type: Article

References (24)

1. Balch CM, Houghton A, Peters L: Cutaneous melanoma, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, pp 1499-1542
2. McClay EF, Mastrangelo MJ: Systemic chemotherapy for melanoma. Semin Oncol 15:569-577, 1988
3. Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
4. McClay EF, Mastrangelo MJ, Bellett RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
5. Richards JM, Gilewski TA, Ramming K, et al: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69:427-429, 1992
6. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1986
7. Dutcher JP, Creekmore S, Weiss GR, et al: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477-485, 1989
8. Parkinson DR, Abrams JS, Wiernik PH, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
9. Dutcher DP, Gaynor ER, Boldt DH, et al: A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9:641-648, 1991
10. Richards JM: Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells. Blood Rev 3:110-119, 1989
11. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
12. Kruit WHJ, Goey SH, Monson JRT, et al: Clinical experience with the combined use of recombinant interleukin-2 and interferon alfa-2a in metastatic melanoma. Br J Haematol 79:84-86, 1991 (suppl 1)
13. Lee KH, Talpaz M, Rothberg JM, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a in cancer patients: A phase I study. J Clin Oncol 7:1726-1732, 1989
14. Mittelman A, Huberman M, Puccio C, et al: A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66:664-669, 1990
15. Atzpodien J, Kirchner H: The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies. Eur J Cancer 27:S88-S91, 1991 (suppl 4)
16. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
17. Richards JM, Priest E, Hamasaki V, et al: Sequential chemoimmunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 10:298, 1991 (abstr 1046)
18. Richards JM, Mehta N, Skosey PJ: Sequential chemoimmunotherapy for the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
19. Hamblin TJ, Davies B, Sadullah S, et al: A phase II study of the treatment of metastatic melanoma with the combination of dacarbazine, cisplatin, interleukin-2 (IL-2) and alfa-interferon (IFN). Pro Am Soc Clin Oncol 10:A1029, 1991 (abstr)
20. Legha S, Plager C, Ring S, et al: A phase II study of biochemotherapy using interleukin-2 and interferon alfa-2a in combination with cisplatin, vinblastine, and DTIC in patients with metastatic melanoma. Proc Am Soc Clin Oncol 11:343, 1992 (abstr 1179)
21. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon-alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
22. Atzpodien J, Lopez Hanninen E, Kirchner H, et al: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31A:876-881, 1995
23. Keilholz U, Goey SH, Punt CJA, et al: A randomized trial of IFN alfa/IL-2 with or without cDDP in advanced melanoma: An EORTC Melanoma Cooperative Group trial. Proc Am Soc Clin Oncol 15:436, 1996 (abstr 1353)
24. Legha S, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7:827-835, 1996